NCT04798222 - Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

September 3, 2021

Study Completion Date

September 3, 2021

Conditions

Heart Failure

Interventions

DRUG

Treatment A

Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.

DRUG

Treatment B

Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.

DRUG

Treatment C

Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition

DRUG

Treatment D

Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.

DRUG

Treatment E

Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.

DRUG

Treatment F

Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 3 in fasted condition.

DRUG

Treatment G

Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.

DRUG

Treatment H

Participants will receive oral dose of dapagliflozin capsule in fasted condition.

Trial Locations (1)

Research Site, Berlin